AU749356B2 - Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis - Google Patents

Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis Download PDF

Info

Publication number
AU749356B2
AU749356B2 AU41837/99A AU4183799A AU749356B2 AU 749356 B2 AU749356 B2 AU 749356B2 AU 41837/99 A AU41837/99 A AU 41837/99A AU 4183799 A AU4183799 A AU 4183799A AU 749356 B2 AU749356 B2 AU 749356B2
Authority
AU
Australia
Prior art keywords
acid
methyl
disease
phthalimidinoglutaric
phthalimidinoglutaric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41837/99A
Other languages
English (en)
Other versions
AU4183799A (en
Inventor
Robert J. D'amato
William E. Fogler
Shawn J Green
John W Madsen
Adonia E. Papathanassiu
Jamshed H. Shah
Glenn M. Swartz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of AU4183799A publication Critical patent/AU4183799A/en
Assigned to CHILDREN'S MEDICAL CENTER CORPORATION reassignment CHILDREN'S MEDICAL CENTER CORPORATION Alteration of Name(s) of Applicant(s) under S113 Assignors: CHILDREN'S MEDICAL CENTER CORPORATION, ENTREMED, INC
Application granted granted Critical
Publication of AU749356B2 publication Critical patent/AU749356B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
AU41837/99A 1998-05-11 1999-05-11 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis Ceased AU749356B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8503798P 1998-05-11 1998-05-11
US60/085037 1998-05-11
US9738498P 1998-08-21 1998-08-21
US60/097384 1998-08-21
US10803798P 1998-11-12 1998-11-12
US60/108037 1998-11-12
PCT/US1999/010287 WO1999058096A2 (fr) 1998-05-11 1999-05-11 Analogues de l'acide 2-phthalimidinoglutarique

Publications (2)

Publication Number Publication Date
AU4183799A AU4183799A (en) 1999-11-29
AU749356B2 true AU749356B2 (en) 2002-06-27

Family

ID=27374997

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41837/99A Ceased AU749356B2 (en) 1998-05-11 1999-05-11 Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis

Country Status (6)

Country Link
EP (1) EP1091726A2 (fr)
JP (1) JP2002514578A (fr)
KR (1) KR100699968B1 (fr)
AU (1) AU749356B2 (fr)
CA (1) CA2331461C (fr)
WO (1) WO1999058096A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
JP4361273B2 (ja) 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
CA2504263A1 (fr) * 2002-10-31 2004-05-21 Celgene Corporation Methodes d'utilisation et compositions contenant des substances medicamenteuses d'inhibition selective des cytokines pour traiter et controler la degenerescence
US7776907B2 (en) 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
CN1867331B (zh) 2003-09-17 2010-05-26 美国政府健康及人类服务部 作为TNF-α调节剂的沙利度胺类似物
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN102603610B (zh) * 2012-02-21 2014-07-09 四川大学 1,3-二氢-1-氧-2h-异吲哚类化合物、其制备方法和用途
CN104045594B (zh) * 2012-02-21 2016-08-17 四川大学 一类1,3-二氢-1-氧-2h-异吲哚类化合物及其用途
US9617212B2 (en) 2013-12-17 2017-04-11 Controlled Chemicals, Inc. Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors
CN109467550B (zh) * 2017-12-31 2022-02-18 苏州亚科科技股份有限公司 一种邻苯二甲酰胺基-l-谷氨酸酐的合成方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4422237A1 (de) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese

Also Published As

Publication number Publication date
KR20010052332A (ko) 2001-06-25
AU4183799A (en) 1999-11-29
WO1999058096A3 (fr) 2000-05-18
WO1999058096A9 (fr) 2000-07-13
CA2331461C (fr) 2008-10-07
EP1091726A2 (fr) 2001-04-18
KR100699968B1 (ko) 2007-03-28
JP2002514578A (ja) 2002-05-21
WO1999058096A2 (fr) 1999-11-18
CA2331461A1 (fr) 1999-11-18

Similar Documents

Publication Publication Date Title
US6673828B1 (en) Analogs of 2-Phthalimidinoglutaric acid
US7812169B2 (en) Method of synthesis of 4-amino-thalidomide enantiomers
CA2457319C (fr) Synthese et activite antitumorale d'analogues de thalidomide substitues par azote
AU2002253795A1 (en) Synthesis of 4-Amino-Thalidomide enantiomers
AU2002323063A1 (en) Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
JP4065373B2 (ja) サリドマイドを有効成分とする医薬品製剤
AU749356B2 (en) Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis
WO2005051357A1 (fr) Agents antiangiogenes

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND INVENTION TITLE TO READ "ANALOGS OF 2-PHTHALIMIDINOGLUTARIC ACID AND THEIR USE AS INHIBITORS OF ANGIOGENESIS"

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT TO INCLUDE THE CHILDREN'S MEDICAL ENTER CORPORATION AND EMEND THE NAME OF THE INVENTOR TO INCLUDE ROBERT J D'AMATO

PC1 Assignment before grant (sect. 113)

Owner name: THE CHILDREN'S MEDICAL CENTER CORPORATION

Free format text: THE FORMER OWNER WAS: ENTREMED, INC, THE CHILDREN'S MEDICAL CENTER CORPORATION

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired